article thumbnail

Commissioner Makary Charts a New Course for FDA at FDLI Annual Conference

FDA Law

Livornese Dr. Marty Makary took the stage on Thursday at the Food and Drug Law Institutes Annual Conference , continuing the tradition of Commissioners speaking at this event, but with a tone and tempo distinctly his own. Claud & Deborah L.

article thumbnail

The MAHA Assessment’s Implications: Drugs (Part One)

FDA Law

There are also drugs the Assessment identifies as being used off-label without high-quality evidence or for uses that are approved but without rigorous true placebo-controlled trials (namely vaccines) and/or with known safety concerns. We will continue to monitor these developments as they come.

article thumbnail

FDA-Approved Labeling: Is Enough Enough?

FDA Law

FDA did, however, try to identify safety issues through the medical literature and (after 2007 when mandatory safety reporting for OTC human drug products marketed without an approved application became effective) through the adverse event reporting system. Just like it was over a decade ago in Pliva v. Take, for example, sunscreens.